Clinical trials: Human NiV Infection
Influenza, Human
Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
A Phase 3, randomized, observer-blinded, active-controlled trial to evaluate the immunogenicity and safety of a recombinant quadrivalent nanoparticle influenza vaccine with Matrix-M1 adjuvant (NanoFlu) compared with a licensed…
- Trial name
- NCT04120194
- Testing
- NanoFlu, Fluzone Quadrivalent
- Where
- 19 sites in United States
- Volunteers
- 2,654 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza, Human
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
A Phase 2 trial to confirm the dose and formulation, demonstrate adjuvant effect, and evaluate the safety and tolerability of a single intramuscular injection of Quad-NIV with or without Matrix-M1 adjuvant in healthy adults ≥ 65…
- Trial name
- NCT03658629
- Testing
- NanoFlu (Quad-NIV), Matrix-M Adjuvant, Fluzone HD
- Where
- 14 sites in United States
- Volunteers
- 1,375 people, healthy volunteers welcome
- Sponsor
- Novavax